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INTRODUCTION
Diabetes mellitus is a syndrome that
is characterized by chronic hyperglycemia
and disturbances of carbohydrate, fat, and
protein metabolism [1]. The association of
hyperglycemia and altering of lipid para-
meters present a major risk of cardiovas-
cular diseases in diabetic patients [2, 3].
The lowering of lipid concentration
through dietary or drugs therapy seems to
be associated with a decrease in the risk of
vascular disease [4]. Since currently avail-
able hypolipidemic agents lack desired
properties of an ideal drug, researchers are
involved to find out an effective, safe, and
less expensive drug.
Coumarin, a phenolic compound pre-
sent in human dietary fruits and vegeta-
bles, is known to have antioxidant poten-
tial like vitamin E (a-tocopherol) and have
lipid lowering potential [5]. Umbelliferone
(UMB)† (7-hydroxycoumarin), a deriva-
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The aim of the study was to evaluate blood glucose and lipid lowering effects of
Umbelliferone (UMB) in streptozotocin (STZ) diabetic rats. Male albino Wistar rats (180 to
200 g) were induced diabetes by administration of STZ (40 mg/kg) intraperitonially. Normal
and diabetic rats were treated with UMB in 10 percent dimethyl sulfoxide (DMSO) for 45
days. Diabetic rats had increased plasma glucose and decreased insulin, total proteins
(TP), and albumin in addition to decreased food intake and body weight. Elevation in total
cholesterol (TC), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein
cholesterol (VLDL-C), triglycerides (TG), free fatty acids (FFA), and phospholipids (PL),
and reduction in high density lipoprotein cholesterol (HDL-C) in the plasma were observed.
Liver and kidney tissues of diabetic rats had elevation in the levels of TC, TG, FFA, and PL.
Treatment with UMB decreased plasma glucose and increased insulin, TP, and albumin
apart from food intake and body weight. In UMB-treated diabetic rats, plasma and tissue
TC, TG, PL and FFA, and plasma LDL-C, VLDL-C, and HDL-C reversed to near normal.
Thus, reduction of blood glucose and lipid profiles indicates that UMB has antidiabetic and
antihyperlipidemic effects in diabetic rats.tive of coumarin, is a benzopyrone in
nature and is present in the edible fruits,
golden apple (Aegle marmelos Correa)
[6], and bitter orange (Citrus aurantium)
[7]. The parent compound coumarin has
been reported to reduce blood glucose
level [8]. We have reported that UMB has
antioxidant activity [9], but no detailed
study has been carried out on the effect of
UMB on blood glucose, plasma insulin,
and protein and lipid profiles in streptozo-
tocin (STZ)-diabetic rats. Hence, the pre-
sent study was designed to investigate the
effect of UMB on lipid profiles in plasma
and tissues such as liver and kidney, and
protein profiles in the plasma of STZ-dia-
betic rats. The structure of UMB is depict-
ed in Figure 1.
MATERIALS AND METHODS
Animals
Male albino rats of Wistar strain with
a body weight ranging from 180 to 200 g,
were procured from Central Animal
House, Department of Experimental
Medicine, Rajah Muthiah Medical College
and Hospital, Annamalai University, and
were maintained in an air conditioned
room (25 ﾱ 1oC) with a 12-hour light/12-
hour dark cycle. Standard pellets (pur-
chased from Pranav Agro Industries, Ltd.,
Pune, India) and water was provided ad
libitum. Studies were carried out in accor-
dance with Indian National Law on
Animal Care and Use, and the study was
approved by the Ethical Committee of
Rajah Muthiah Medical College and
Hospital (Reg. No: 160/1999/CPCSEA
[Committee for the Purpose of Control and
Supervision of Experiments on Animals]),
Annamalai University, Annamalainagar,
Tamilnadu, India.
Chemicals
Streptozotocin was purchased from
Sigma-Aldrich, St. Louis, United States.
UMB was procured from Carl Roth GmbH
& Co, Germany. All the other chemicals
were of analytical grade obtained from E.
Merck, Germany, and HIMEDIA, India.
Experimental induction of diabetes
The animals were rendered diabetic
by a single intraperitonial injection of STZ
(40 mg/kg b-wt) in freshly prepared citrate
buffer (0.1 M, pH 4.5) after an overnight
fast. STZ-injected animals were given 20
percent glucose solution for 24 hours to
prevent initial drug-induced hypoglycemic
mortality. STZ-injected animals exhibited
massive glycosuria (determined by
Benedict's qualitative test), and diabetes in
STZ rats was confirmed by measuring
fasting blood glucose concentration by
glucose oxidase method, 96 hours after
injection with STZ. The animals with
blood glucose above 235 mg/dl were con-
sidered to be diabetic and used for the
experiment.
Experimental design
The animals were randomly divided
into five groups of six animals each as
given below. The UMB and glibenclamide
were administered intraperitonially once a
day using vehicle solution (10 percent
DMSO).
Group I: Normal control (10 percent DMSO)
Group II: Normal + UMB (30 mg/kg/b-wt in
10 percent DMSO)
Group III: Diabetic control (10 percent
DMSO)
Group IV: Diabetic + UMB (30 mg/kg/b-wt
in 10 percent DMSO)
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Figure 1. Structure of UMB.Table 2. Effect of UMB on body weight and food intake in diabetic rats.
Body weight (g) Average
food intake
Group 0 day 45th day (g/day)
Normal control 181.33 ﾱ 4.22 198.83 ﾱ 6.88b 15.35 ﾱ 0.93a,b
Normal + UMB 179.42 ﾱ 4.71 196.16 ﾱ 5.07b 16.15 ﾱ 1.25a
(30 mg/kg/b-wt)
Diabetic control 180.08 ﾱ 5.84 150.50 ﾱ 4.92a 12.25 ﾱ 1.01c
Diabetic + UMB 178.33 ﾱ 5.00 197.57 ﾱ 5.84b 14.10 ﾱ 1.13b
(30 mg/kg/b-wt)
Diabetic + glibenclamide 183.00 ﾱ 4.69 210.00 ﾱ 6.00c 14.71 ﾱ 1.05b
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a common super-
script differ significantly at p < .05 (Duncan’s Multiple Range Test).
Group V: Diabetic + glibenclamide (600
ﾵg/kg b-wt in 10 percent DMSO)
After 45 days of treatment, the 12
hour-fasted animals were anesthetized
between 8:00 a.m. and 9:00 a.m., using
Ketamine (24 mg/kg b-wt) (intramuscular
injection) and sacrificed by decapitation.
Blood was collected in tubes with a mix-
ture of potassium oxalate and sodium flu-
oride (1:3) for the estimation of blood glu-
cose and in tubes with ethylenediamine
tetra acetic acid (EDTA) for the estimation
of total cholesterol (TC), triglycerides
(TG), free fatty acids (FFA), phospho-
lipids (PL), high density lipoprotein
(HDL-C), and protein profiles such as
total proteins (TP), albumin, and globulin
(A/G) ratio. Tissues such as liver and kid-
ney were collected for the estimation of
TC, TG, FFA, and PL.
Biochemical determinations
Blood glucose was estimated by the
method of Trinder using reagent kit [10].
The insulin in the rat plasma was mea-
sured by method of Burgi et al [11].
Plasma and tissue lipids were extracted by
the methods of Folch et al [12]. Plasma
and tissue TC, TG, FFA, and PL were esti-
mated by the methods of Siedel et al [13],
Foster and Dunn [14], Falholt et al [15],
and Zilversmit and Davis [16], respective-
ly. Plasma HDL-C was estimated by the
method of Warnick et al [17]. LDL-C and
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Table 1. Effect of UMB on blood glucose and plasma insulin in diabetic rats.
Blood glucose (mg/dl)
Insulin
Group 0 day 45th day (ﾵU/ml)
Normal control 79.60 ﾱ 5.25 82.44 ﾱ 2.68b 18.04 ﾱ 0.77a,b
Normal + UMB 82.14 ﾱ 3.19 74.39 ﾱ 4.17a 18.73 ﾱ 0.84a
(30 mg/kg/b-wt)
Diabetic control 240.47 ﾱ 5.82 289.28 ﾱ 3.18d 5.38 ﾱ 0.37c
Diabetic + UMB 244.63 ﾱ 6.29 114.28 ﾱ 5.71c 17.11 ﾱ 0.66b
(30 mg/kg/b-wt)
Diabetic + glibenclamide 242.85 ﾱ 5.04 107.23 ﾱ 7.23c 17.49 ﾱ 0.60b
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a common super-
script differ significantly at p < .05 (Duncan’s Multiple Range Test).Table 4. Effect of UMB on FFA and PL in the plasma of diabetic rats.
FFA PL
Group (mg/dl) (mg/dl)
Normal control 81.33 ﾱ 6.02a,b 90.93 ﾱ 7.18b
Normal + UMB (30 mg/kg/b-wt) 74.66 ﾱ 4.13a 84.48 ﾱ 3.14a
Diabetic control 156.00 ﾱ 4.38d 143.73 ﾱ 7.20d
Diabetic + UMB (30 mg/kg/b-wt) 96.00 ﾱ 7.15c 106.18 ﾱ 4.81c
Diabetic + glibenclamide (600 ﾵg/kg/b-wt) 88.00 ﾱ 6.82b 100.60 ﾱ 4.37c
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (Duncan’s Multiple Range Test).
VLDL-C were calculated by Friedwald's
formula [18]. Plasma TP and albumin
were estimated by the methods of Gornall
et al [19] and Corcoran and Durnan [20],
respectively.
Statistical analysis
Values are given as means ﾱ SD for
six rats in each group. Data were analyzed
by one-way analysis of variance
(ANOVA) followed by Duncan's Multiple
Range Test (DMRT) using SPSS-10. The
limit of statistical significance was set at p
< .05.
RESULTS
The levels of plasma insulin and
blood glucose in diabetic rats are given in
the Table 1. Diabetic rats exhibited
decreased level of plasma insulin and an
elevated level of blood glucose as com-
pared with normal control rats. Treatment
with UMB and glibenclamide showed the
reversal of blood glucose and plasma
insulin to near normal levels. The effect of
UMB on body weight and food intake is
given in the Table 2. Decreased body
weight and food intake were observed in
diabetic rats as compared with normal
control rats, and treatment with UMB had
increased body weight and food intake to
near normalcy.
Table 3 shows the levels of TC, TG,
LDL-C, VLDL-C, and HDL-C in the plas-
ma of diabetic rats. The diabetic rats had
elevated levels of plasma TC, TG, LDL-C,
and VLDL-C and decreased level of HDL-
C as compared with normal control rats.
Diabetic rats treated with UMB and
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Table 3. Effect of UMB TC, TG, LDL-C, VLDL-C, and HDL-C in the plasma of diabetic
rats.
TC TG LDL-C VLDL-C HDL-C
Group (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl)
Normal control 84.33 ﾱ 1.50b 62.1 ﾱ 5.66a 21.14 ﾱ 2.10b 12.42 ﾱ 1.13b 50.76 ﾱ 1.75b
Normal + UMB
(30 mg/kg/b-wt) 79.00 ﾱ 2.09a 55.8 ﾱ 5.57a 18.38 ﾱ 1.42a 11.16 ﾱ 1.11a 53.51 ﾱ 1.05a
Diabetic control 136.00 ﾱ 2.82e178.2 ﾱ 4.82d 78.24 ﾱ 4.06e 35.64 ﾱ 1.96e 28.85 ﾱ 1.25e
Diabetic + UMB 96.33 ﾱ 3.10d 78.3 ﾱ 7.23c 36.01 ﾱ 2.74d 14.22 ﾱ 1.26c 46.06 ﾱ 2.62d
(30 mg/kg/b-wt)
Diabetic + glibenclamide 91.00 ﾱ 2.09c71.1 ﾱ 6.31b 27.16 ﾱ 2.40c 15.66 ﾱ 1.44d 48.18 ﾱ 3.56c
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a com-
mon superscript differ significantly at p < .05 (Duncan’s Multiple Range Test).glibenclamide reversed serum lipid pro-
files to near normal levels.
Table 4 represents the levels of FFA
and PL in the plasma of diabetic rats. The
diabetic rats had elevated levels of plasma
FFAand PLas compared with normal con-
trol rats. Diabetic rats treated with UMB
and glibenclamide reversed plasma lipid
profiles to near normal levels.
The levels of TC, TG, FFA, and PL in
liver and kidney of diabetic rats are given
in Tables 5 and 6. The diabetic rats had
elevated levels of tissue TC, TG, FFA, and
PL when compared with normal control
rats. Diabetic rats treated with UMB and
glibenclamide reversed tissue lipid pro-
files to near normal levels.
The levels of TP, albumin, globulin,
and albumin/globulin ratio in the plasma
of diabetic rats are presented in the Table
7. The diabetic rats had decreased levels of
plasma total proteins, albumin, globulins
and albumin/globulin ratio when com-
pared with normal control rats.After treat-
ment with UMB and glibenclamide, TP,
albumin, globulins, and albumin/globulin
ratio were brought back to near normal
levels.
DISCUSSION
In type 2 diabetes, insulin secretion is
defective and insufficient to compensate
for insulin resistance which may improve
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Table 5. Effect of UMB on TC, TG, FFA, and PL in the liver of diabetic rats.
TC TG FFA PL
(mg/100 g (mg/100 g (mg/100 g (mg/100 g
Group tissue) tissue) tissue) tissue)
Normal control 341.33 ﾱ 7.29a 315.00 ﾱ 8.04a 790.40 ﾱ 14.45a,b 1936.00 ﾱ 39.35b
Normal + UMB
(30 mg/kg/b-wt) 332.00 ﾱ 4.38a 307.50 ﾱ 6.77a 784.00 ﾱ 12.08a 1899.33 ﾱ 33.12b
Diabetic control 648.00 ﾱ 3.64d 730.50 ﾱ 10.52c 1382.53 ﾱ 17.17d 3740.00 ﾱ 39.35a
Diabetic + UMB 368.00 ﾱ 11.49c 334.50 ﾱ 6.54b 819.20 ﾱ 15.67c 1796.66 ﾱ 33.12d
(30 mg/kg/b-wt)
Diabetic + glibenclamide 354.40 ﾱ 6.76b 327.00 ﾱ 4.64b 807.04 ﾱ 10.70b,c 1848.00 ﾱ 39.35c
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a common super-
script differ significantly at p < .05 (Duncan’s Multiple Range Test).
Table 6. Effect of UMB on TC, TG, FFA, and PL in the kidneys of diabetic rats.
TC TG FFA PL
(mg/100 g (mg/100 g (mg/100 g (mg/100 g
Group tissue) tissue) tissue) tissue)
Normal control 377.33 ﾱ 9.35b 265.50 ﾱ 9.43a,b 374.40 ﾱ 20.13a 2024.00 ﾱ 43.15a
Normal + UMB
(30 mg/kg/b-wt) 364.00 ﾱ 8.39a 259.50 ﾱ 6.77a 364.80 ﾱ 17.17a 1980.00 ﾱ 39.35a
Diabetic control 678.13 ﾱ 3.84d 006.39 ﾱ 8.04d 919.68 ﾱ 12.56d 2912.00 ﾱ 62.32d
Diabetic + UMB 414.66 ﾱ 11.77c 282.00 ﾱ 7.34c 426.00 ﾱ 15.67c 2148.66 ﾱ 51.43c
(30 mg/kg/b-wt)
Diabetic + glibenclamide 387.46 ﾱ 7.53b 273.00 ﾱ 6.28b,c 393.60 ﾱ 8.67b 2090.00 ﾱ 46.14b
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a common super-
script differ significantly at p < .05 (Duncan’s Multiple Range Test).with weight reduction and/or pharmaco-
logical treatment of hyperglycemia but is
seldom restored to normal [21]. UMB as a
pharmacological agent may improve the
condition. Further, as UMB is having an
antihyperlipidemic effect it may also
decrease insulin resistance and improve the
condition. It is now well established that
STZ selectively destroys the pancreatic
cells and produces hyperglycemia [22],
which is evidenced by the decreased level
of plasma insulin. In a previous report,
coumarin has been reported to reduce
blood glucose level [8]. Coumarin may be
a prodrug, and 7-hydroxycoumarin is the
pharmacologically active agent [23].
Treatment with UMB and glibenclamide
showed the reversal of blood glucose to
near normal levels which is supported by
the elevated level of plasma insulin. STZ-
induced diabetes is characterized by severe
loss in body weight [24], and the loss may
be due to degradation of structural proteins
since structural proteins are known to con-
tribute to the body weight [25]. In our
study, weight loss and decreased food
intake were observed, and treatment with
UMB reversed the weight loss and food
intake, which may be due to increased
secretion of insulin by UMB.
The levels of serum lipids are elevat-
ed in diabetes mellitus, and such an eleva-
tion represents a risk factor for coronary
heart disease [26]. Lowering of serum and
tissue lipids through diet or drug seems to
be associated with a decrease in the risk of
vascular disease [27]. The abnormal high
concentration of serum lipids in diabetic
subjects is mainly due to increase in the
mobilization of free fatty acids from fat
deposits [28] since insulin is required for
the inhibition of hormone-sensitive lipase.
On the other hand, glucagon and other
hormones enhance lipolysis. The marked
hyperlipidemia that characterizes the dia-
betic state may, therefore, be regarded as a
consequence of uninhibited actions of
lipolytic hormones on the fat deposits
[29]. Diabetic rats treated with UMB and
glibenclamide brought TC and TG back to
near normal levels, which could be due to
an increase in insulin secretion, which, in
turn, inhibits hormone sensitive lipase and
increases the utilization of glucose and
thereby decreasing the mobilization of free
fatty acids from the fat depots. The
decreased level of FFA is also associated
with decreased actions of lipolytic hor-
mones, which, in turn, decreased the activ-
ity of hormone sensitive lipases on fat
deposits.
High levels of TC and, more impor-
tantly, LDL-C are major coronary risk fac-
tors [30], and low plasma levels of HDL-
C is a relevant cardiovascular risk factor
[31]. In diabetic rats, the rise inTC andTG
192 Ramesh and Pugalendi: Antihyperlipidemic effect of UMB in diabetes
Table 7. Effect of UMB on TP, albumin, globulin, and A/G in the plasma of diabetic rats.
Total
protein Albumin Globulin A/G
Group (g/dl) (g/dl) (g/dl) ratio
Normal control 7.08 ﾱ .38b 3.85 ﾱ .27b 3.16 ﾱ .29b 1.21 ﾱ .07b
Normal + UMB
(30 mg/kg/b-wt) 8.28 ﾱ .42a 4.37 ﾱ .31a 3.86 ﾱ .25a 1.48 ﾱ .08a
Diabetic control 4.33 ﾱ .37d 1.93 ﾱ .18d 2.35 ﾱ .18d 0.82 ﾱ .06d
Diabetic + UMB 6.18 ﾱ .45c 3.21 ﾱ .28c 2.86 ﾱ .21c 1.12 ﾱ .10c
(30 mg/kg/b-wt)
Diabetic + glibenclamide 6.50 ﾱ .49c 3.50 ﾱ 21b,c 3.01 ﾱ .27b,c 1.16 ﾱ .09c
(600 ﾵg/kg/b-wt)
Values are given as means ﾱ SD from six rats in each group. Values not sharing a common super-
script differ significantly at p < .05 (Duncan’s Multiple Range Test).is associated with the increase in LDL-C
and VLDL-C and decrease in HDL-C. In
our study, the diabetic rats treated with
UMB showed an elevation in HDL-C and
reduction in LDL-C and VLDL-C as evi-
denced by decreased levels of TC and TG.
Thus, UMB could alleviate the risk of car-
diovascular diseases.
Phospholipids are vital components of
biomembranes and play an important role
in the transport of triglycerides [32]. In
STZ-diabetic rats, the elevated level of
phospholipids may be due to the elevated
levels of FFA[33] and TC, which can pro-
mote the synthesis of phospholipids [34].
In UMB-treated diabetic rats, the
decreased level of phospholipids may be
due to decreased levels of TC and FFA.
Insulin generally has an anabolic
effect on protein metabolism in that it
stimulates protein synthesis and retards
protein degradation [35]. Previous reports
show that protein synthesis is decreased in
all tissues due to decreased production of
ATP and absolute or relative deficiency of
insulin [36], which may be responsible for
the decreased level of plasma proteins in
diabetic rats. In our study, the elevated
level of plasma total proteins, albumin,
and globulins may be related with
increased levels of plasma insulin in dia-
betic rats treated with UMB and gliben-
clamide. Rasch and Mogensen [37] have
reported that the plasma A/G ratio was
lower in diabetic animals. Increased pro-
tein catabolism in diabetes might have
induced a direct adverse effect on the syn-
thesis and secretion of albumin. Diabetic
rats treated with UMB and glibenclamide
also brought A/G ratios back to near nor-
mal level.
CONCLUSION
Thus, our findings demonstrate that
UMB has an antidiabetic effect, which is
evidenced by decreased blood glucose,
elevated plasma insulin and protein pro-
file, and hypolipidemic effect, which is
evidenced by the decreased levels of TC,
TG, LDL-C, VLDL-C, FFA, and PL, and
elevated levels of HDL-C in diabetic rats.
Since UMB is a natural product, combina-
tion with reduced dosage of already exist-
ing antidiabetic drug may prevent side-
effects. This requires further investigation.
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